tiprankstipranks
Lakefront Biotherapeutics (LKFT)
NASDAQ:LKFT
US Market
LKFT
Lakefront Biotherapeutics
RESEARCH TOOLSreports
Want to see LKFT full AI Analyst Report?

Lakefront Biotherapeutics (LKFT) Stock Forecast & Price Target

549 Followers
See the Price Targets and Ratings of:

LKFT Analyst Ratings

Moderate Sell
2Ratings
Moderate Sell
0 Buy
1 Hold
1 Sell
Based on 2 analysts giving stock ratings to
Lakefront
Biotherapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LKFT Stock 12 Month Forecast

Average Price Target

$25.00
▼(-14.62% Downside)
Based on 2 Wall Street analysts offering 12 month price targets for Lakefront Biotherapeutics in the last 3 months. The average price target is $25.00 with a high forecast of $28.00 and a low forecast of $22.00. The average price target represents a -14.62% change from the last price of $29.28.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","36":"$36","24.75":"$24.8","28.5":"$28.5","32.25":"$32.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,24.75,28.5,32.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28,28,28,28,28,28,28,28,28,28,28,28,28,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28,27.76923076923077,27.53846153846154,27.307692307692307,27.076923076923077,26.846153846153847,26.615384615384617,26.384615384615383,26.153846153846153,25.923076923076923,25.692307692307693,25.46153846153846,25.23076923076923,{"y":25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28,27.53846153846154,27.076923076923077,26.615384615384617,26.153846153846153,25.692307692307693,25.23076923076923,24.76923076923077,24.307692307692307,23.846153846153847,23.384615384615383,22.923076923076923,22.46153846153846,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.78,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29.2,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.87,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":32.71,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":31.16,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":35.04,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":31.78,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":31.13,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":32.7,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":34.23,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":34.09,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29.76,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$28.00Average Price Target$25.00Lowest Price Target$22.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on LKFT
Brian Abrahams
RBC Capital
RBC Capital
$28
Hold
-4.37%
Downside
Reiterated
05/13/26
RBC Capital Sticks to Its Hold Rating for Lakefront Biotherapeutics (LKFT)
Morgan Stanley Analyst forecast on LKFT
Judah Frommer
Morgan Stanley
Morgan Stanley
$22
Sell
-24.86%
Downside
Reiterated
03/16/26
Morgan Stanley Keeps Their Sell Rating on Galapagos (GLPG)
Bank of America Securities Analyst forecast on LKFT
Jason Gerberry
Bank of America Securities
Bank of America Securities
$25→$28
Sell
-4.37%
Downside
Reiterated
11/06/25
Bank of America Securities Keeps Their Sell Rating on Galapagos (GLPG)
Jefferies Analyst forecast on LKFT
Faisal Khurshid
Jefferies
Jefferies
$29→$40
Buy
36.61%
Upside
Upgraded
10/22/25
Galapagos upgraded to Outperform from Market Perform at LeerinkGalapagos upgraded to Outperform from Market Perform at Leerink
Raymond James Analyst forecast on LKFT
Sean McCutcheon
Raymond James
Raymond James
―
Hold
―
Reiterated
07/24/25
Galapagos (GLPG) Receives a Hold from Raymond James
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on LKFT
Brian Abrahams
RBC Capital
RBC Capital
$28
Hold
-4.37%
Downside
Reiterated
05/13/26
RBC Capital Sticks to Its Hold Rating for Lakefront Biotherapeutics (LKFT)
Morgan Stanley Analyst forecast on LKFT
Judah Frommer
Morgan Stanley
Morgan Stanley
$22
Sell
-24.86%
Downside
Reiterated
03/16/26
Morgan Stanley Keeps Their Sell Rating on Galapagos (GLPG)
Bank of America Securities Analyst forecast on LKFT
Jason Gerberry
Bank of America Securities
Bank of America Securities
$25→$28
Sell
-4.37%
Downside
Reiterated
11/06/25
Bank of America Securities Keeps Their Sell Rating on Galapagos (GLPG)
Jefferies Analyst forecast on LKFT
Faisal Khurshid
Jefferies
Jefferies
$29→$40
Buy
36.61%
Upside
Upgraded
10/22/25
Galapagos upgraded to Outperform from Market Perform at LeerinkGalapagos upgraded to Outperform from Market Perform at Leerink
Raymond James Analyst forecast on LKFT
Sean McCutcheon
Raymond James
Raymond James
―
Hold
―
Reiterated
07/24/25
Galapagos (GLPG) Receives a Hold from Raymond James
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Lakefront Biotherapeutics

3 Months
xxx
Success Rate
7/14 ratings generated profit
50%
Average Return
-0.78%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -0.78% per trade.
1 Year
Judah FrommerMorgan Stanley
Success Rate
11/14 ratings generated profit
79%
Average Return
+4.74%
Copying Judah Frommer's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +4.74% per trade.
2 Years
xxx
Success Rate
11/14 ratings generated profit
79%
Average Return
+8.60%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +8.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LKFT Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
1
1
1
2
2
Sell
6
7
7
5
2
Strong Sell
0
0
0
0
0
total
7
8
8
7
4
In the current month, LKFT has received 0 Buy Ratings, 2 Hold Ratings, and 2 Sell Ratings. LKFT average Analyst price target in the past 3 months is 25.00.
Each month's total comprises the sum of three months' worth of ratings.

LKFT Financial Forecast

LKFT Earnings Forecast

Next quarter’s earnings estimate for LKFT is -$0.82 with a range of -$1.14 to -$0.51. The previous quarter’s EPS was $0.25. LKFT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year LKFT has Performed in-line its overall industry.
Next quarter’s earnings estimate for LKFT is -$0.82 with a range of -$1.14 to -$0.51. The previous quarter’s EPS was $0.25. LKFT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year LKFT has Performed in-line its overall industry.

LKFT Sales Forecast

Next quarter’s sales forecast for LKFT is $6.20M with a range of $5.18M to $7.22M. The previous quarter’s sales results were $7.58M. LKFT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year LKFT has Performed in-line its overall industry.
Next quarter’s sales forecast for LKFT is $6.20M with a range of $5.18M to $7.22M. The previous quarter’s sales results were $7.58M. LKFT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year LKFT has Performed in-line its overall industry.

LKFT Stock Forecast FAQ

What is LKFT’s average 12-month price target, according to analysts?
Based on analyst ratings, Lakefront Biotherapeutics’s 12-month average price target is 25.00.
    What is LKFT’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for LKFT, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is LKFT a Buy, Sell or Hold?
        Lakefront Biotherapeutics has a consensus rating of Moderate Sell which is based on 0 buy ratings, 1 hold ratings and 1 sell ratings.
          What is Lakefront Biotherapeutics’s price target?
          The average price target for Lakefront Biotherapeutics is 25.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $28.00 ,the lowest forecast is $22.00. The average price target represents -14.62% Decrease from the current price of $29.28.
            What do analysts say about Lakefront Biotherapeutics?
            Lakefront Biotherapeutics’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 2 Wall Streets Analysts.
              How can I buy shares of LKFT?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.